Target Price | $2.00 |
Price | $0.10 |
Potential |
1,974.69%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a Lyra Therapeutics Inc price target 2026.
The average Lyra Therapeutics Inc target price is $2.00.
This is
1,974.69%
register free of charge
|
|
A rating was issued by 3 analysts: 0 Analysts recommend Lyra Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lyra Therapeutics Inc stock has an average upside potential 2026 of
1,974.69%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 1.53 | 1.15 |
1.92% | 25.03% | |
Net Margin | -6,200.47% | -2,412.35% |
16.53% | 61.09% |
3 Analysts have issued a sales forecast Lyra Therapeutics Inc 2025 . The average Lyra Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Lyra Therapeutics Inc 2025 . The average Lyra Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.44 | -0.42 |
14.29% | 70.83% | |
P/E | negative | |
EV/Sales | 6.98 |
1 Analysts have issued a Lyra Therapeutics Inc forecast for earnings per share. The average Lyra Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Lyra Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.